Sattva Sukun Lifecare reported a standalone net loss of ₹23.38 lakh for the first quarter of FY27, marking a significant turnaround from the net profit of ₹65.14 lakh recorded in Q1FY26. The deterioration in profitability was driven by an 80.7% year-on-year decline in total income from operations to ₹23.41 lakh, coupled with a rise in total expenses to ₹60.77 lakh from ₹52.43 lakh in the previous year’s corresponding period.

The company submitted its unaudited financial results (standalone and consolidated) to the Bombay Stock Exchange on August 5, 2026, in compliance with Regulation 47(l)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were published in Mumbai Lakshadweep and Active Times newspapers. Mit Tarunkumar Brahmbhatt, Managing Director, signed the financial statement dated August 4, 2026.

Financial Performance

The sharp contraction in revenue highlights operational challenges during the quarter. While income fell drastically, expenses increased by approximately 15.9% compared to Q1FY25, leading to a widening pre-tax loss.

On a consolidated basis, the group reported a net loss of ₹16.01 lakh after tax, compared to a profit of ₹65.14 lakh in Q1FY26. Consolidated income from operations stood at ₹76.07 lakh, a decline from ₹121.61 lakh in the prior year period. Consolidated expenses rose to ₹107.11 lakh from ₹52.43 lakh.

Quarter-on-Quarter Movement

Compared to the preceding quarter (Q4FY26), the standalone net loss narrowed to ₹23.38 lakh from ₹56.97 lakh. However, this improvement coincided with a further drop in revenue, which fell to ₹23.41 lakh from ₹31.41 lakh in Q4FY26. Expenses also decreased significantly to ₹60.77 lakh from ₹106.30 lakh in the previous quarter.

What the Numbers Show

The divergence between revenue collapse and expense inflation is the critical concern for investors. While income plummeted by over 80% year-on-year, operating expenses did not scale down proportionally, rising nearly 16%. This suggests fixed cost rigidity or specific one-time expenditures that eroded margins entirely. The basic earnings per share turned negative at -₹0.01, reflecting the impact on shareholder value. With paid-up equity capital remaining stable at ₹3,836.01 lakh, the dilution effect is limited, but the profitability reversal signals a need for operational restructuring or revenue recovery strategies in subsequent quarters.

Sattva Sukun Lifecare reported a standalone net loss of ₹22.35 lakh for the quarter ended June 30, 2026, reversing from a net profit of ₹65.14 lakh in the corresponding period of the previous year. The deterioration was driven by an 80.7% year-on-year collapse in net sales to ₹23.40 lakh from ₹121.55 lakh, coupled with a 15.9% rise in total expenses to ₹60.77 lakh. This performance underscores significant operational headwinds for the distributor as it navigates shrinking revenue streams and elevated cost structures.

The Board of Directors approved the unaudited financial results on August 4, 2026, in compliance with Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory Auditors S S R V & Associates issued a limited review report on both standalone and consolidated figures, confirming no material misstatements. Additionally, the board reviewed the statement of deviations regarding the use of proceeds from the rights issue dated July 7, 2025.

Financial Performance Overview

Standalone net sales declined sharply, while other income remained negligible at zero for the current quarter, contrasting with ₹1.48 lakh in the preceding quarter (Q4FY26). Total expenses surged due to increased purchases of stock-in-trade (₹56.08 lakh vs ₹46.31 lakh YoY) and higher employee benefit expenses (₹7.50 lakh vs ₹5.94 lakh). Although inventory changes provided a credit of ₹43.57 lakh, it was insufficient to offset the revenue drop. Consequently, profit before tax stood at a loss of ₹37.37 lakh, compared to a profit of ₹69.18 lakh in Q1FY25.

On a consolidated basis, net sales fell to ₹64.45 lakh from ₹121.55 lakh in the prior year quarter. Other income contributed ₹11.62 lakh, a marginal increase from ₹0.06 lakh previously. However, total consolidated expenses rose sharply to ₹107.11 lakh from ₹52.43 lakh, primarily due to higher stock purchases (₹194.70 lakh) and employee benefits (₹12.04 lakh). The group reported a consolidated net loss of ₹16.01 lakh, reversing from a profit of ₹65.14 lakh in Q1FY25.

Rights Issue Fund Utilization

The company disclosed deviations in the utilization of funds raised through a rights issue on July 7, 2025. While no deviation was reported for specific objects, the original allocation of ₹4,950 lakh was modified to ₹1,916.16 lakh. As of June 30, 2026, ₹1,891.81 lakh had been utilized. Key allocations included ₹220 lakh for working capital (modified from ₹470 lakh), ₹300 lakh for business expansion (modified from ₹500 lakh), and ₹1,194.16 lakh for investment in existing subsidiary M/s PavaPuri Export Private Limited (modified from ₹3,500 lakh). General corporate purposes saw utilization of ₹116.16 lakh against a modified allocation of ₹116.16 lakh.

What the Numbers Show

The divergence between standalone and consolidated results highlights the impact of inter-company transactions and subsidiary performance. While standalone operations struggled with high inventory costs relative to sales, the consolidated view shows significant other income contributions, suggesting non-operational gains or subsidiary-specific revenues are buffering some losses. However, the overall trend indicates pressure on core distribution margins, with expense growth outpacing any residual income stability. Investors should monitor whether the revised rights issue allocations will stabilize working capital needs in upcoming quarters.